- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S. assuming FDA approval - CARLSBAD, Calif. –(BUSINESS WIRE)–Jun.
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
calendar_today
June 25, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals